Partial oral antibiotic treatment of endocarditis in patients who inject drugs: a case series
Abstract Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in person...
Saved in:
Published in | JAC-antimicrobial resistance Vol. 4; no. 1; p. dlac008 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Oxford University Press
01.03.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.
Objectives
To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.
Methods
Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team.
Results
In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.
Conclusions
These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. |
---|---|
AbstractList | Abstract
Background
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.
Objectives
To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.
Methods
Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team.
Results
In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.
Conclusions
These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team. In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.BACKGROUNDRecent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.OBJECTIVESTo evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team.METHODSConsecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team.In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.RESULTSIn 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.CONCLUSIONSThese data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. Objectives To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Methods Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team. Results In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. Conclusions These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs. |
Author | Stoner, Bobbi Jo Sheridan, Kathleen R. Rivosecchi, Ryan Viehman, J. Alexander Miller, Kaylie Nauriyal, Varidhi Evans, Emily El-Dalati, Sami |
AuthorAffiliation | 1 University of Pittsburgh Medical Center , Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA 4 University of Kentucky Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA 2 University of Pittsburgh Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA 3 University of Pittsburgh Medical Center , Department of Pharmacy, 3501 Terrace Street Pittsburgh, PA 15213, USA |
AuthorAffiliation_xml | – name: 3 University of Pittsburgh Medical Center , Department of Pharmacy, 3501 Terrace Street Pittsburgh, PA 15213, USA – name: 4 University of Kentucky Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA – name: 1 University of Pittsburgh Medical Center , Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA – name: 2 University of Pittsburgh Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA |
Author_xml | – sequence: 1 givenname: Kaylie surname: Miller fullname: Miller, Kaylie – sequence: 2 givenname: Emily surname: Evans fullname: Evans, Emily – sequence: 3 givenname: Kathleen R. surname: Sheridan fullname: Sheridan, Kathleen R. – sequence: 4 givenname: Varidhi surname: Nauriyal fullname: Nauriyal, Varidhi – sequence: 5 givenname: J. Alexander surname: Viehman fullname: Viehman, J. Alexander – sequence: 6 givenname: Ryan surname: Rivosecchi fullname: Rivosecchi, Ryan – sequence: 7 givenname: Bobbi Jo surname: Stoner fullname: Stoner, Bobbi Jo – sequence: 8 givenname: Sami orcidid: 0000-0003-2603-2951 surname: El-Dalati fullname: El-Dalati, Sami email: s.eldalati10@gmail.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35156032$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUUtrFTEYDdJia-3WpQTc6OK2eczk4UKQYrVQ0IUuJXyTSdpcZpJrklH896bc29IWpJs8-M45OSfnBdqLKTqEXlFyQonmp2uwMOfTcQJLiHqGDpngbEUV43v3zgfouJQ1IYT1RHaSPUcHvKe9IJwdop_fINcAE065LRBrGEKqweKaHdTZxYqTxy6OyUIeQw0Fh4g3UEMbFfznOrX72tmKx7xclfcYsIXicHE5uPIS7XuYijve7Ufox_mn72dfVpdfP1-cfbxc2a7TdaVHrkdPAbztRt9pGLjrVd9554XUXmg6gBZSci0sZYIMwgkidcelGjqqLT9CH7a6m2WY3WibtxbHbHKYIf81CYJ5OInh2lyl30YpJvteN4G3O4Gcfi2uVDOHYt00QXRpKYYJpoQSXPQN-uYRdJ2WHFs8w6nQWkmhaEO9vu_ozsrtzzfAyRZgcyolO38HocTctGu27Zpdu43QPSLYUFsP6SZRmP5Pe7elpWXz1BP_ACX3uwg |
CitedBy_id | crossref_primary_10_1093_jacamr_dlaf032 crossref_primary_10_1016_j_cmi_2023_04_005 crossref_primary_10_1093_cid_ciac714 |
Cites_doi | 10.1016/j.idc.2020.06.010 10.1093/ofid/ofz089 10.1093/ofid/ofy132 10.1086/313753 10.1161/CIR.0000000000000296 10.1093/cid/ciaa365 10.1097/ADM.0000000000000693 10.1111/j.1470-9465.2004.00846.x 10.1056/NEJMoa1808312 10.1093/cid/ciaa1126 10.1093/ejcts/ezy325 |
ContentType | Journal Article |
Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. – notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1093/jacamr/dlac008 |
DatabaseName | Oxford Journals Open Access (Activated by CARLI) CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2632-1823 |
ExternalDocumentID | PMC8827559 35156032 10_1093_jacamr_dlac008 10.1093/jacamr/dlac008 |
Genre | Journal Article |
GroupedDBID | 0R~ 53G AAFWJ AAPXW AAVAP ABPTD ABXVV AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS EBS GROUPED_DOAJ IAO IHR INH KSI M~E OK1 ROX RPM TOX 7X7 8C1 8FI 8FJ AAYXX ABEJV ABGNP ABUWG AFKRA AMNDL BENPR CCPQU CITATION FYUFA HMCUK ITC PHGZM PHGZT PIMPY UKHRP NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c449t-9d39df1aafc4df49ab3e5854fef679f691ba9677396c1260b6e60794378b419c3 |
IEDL.DBID | 7X7 |
ISSN | 2632-1823 |
IngestDate | Thu Aug 21 18:13:57 EDT 2025 Fri Jul 11 06:45:02 EDT 2025 Fri Jul 25 21:51:25 EDT 2025 Wed Feb 19 02:26:57 EST 2025 Tue Jul 01 03:54:18 EDT 2025 Thu Apr 24 23:05:02 EDT 2025 Wed Aug 28 03:17:26 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c449t-9d39df1aafc4df49ab3e5854fef679f691ba9677396c1260b6e60794378b419c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-2603-2951 |
OpenAccessLink | https://www.proquest.com/docview/3169987681?pq-origsite=%requestingapplication% |
PMID | 35156032 |
PQID | 3169987681 |
PQPubID | 7097363 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8827559 proquest_miscellaneous_2628686365 proquest_journals_3169987681 pubmed_primary_35156032 crossref_primary_10_1093_jacamr_dlac008 crossref_citationtrail_10_1093_jacamr_dlac008 oup_primary_10_1093_jacamr_dlac008 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-Mar |
PublicationDateYYYYMMDD | 2022-03-01 |
PublicationDate_xml | – month: 03 year: 2022 text: 2022-Mar |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | JAC-antimicrobial resistance |
PublicationTitleAlternate | JAC Antimicrob Resist |
PublicationYear | 2022 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Rapoport (2022031017575820000_dlac008-B6) 2018; 5 Kimmel (2022031017575820000_dlac008-B10) 2021; 15 Marks (2022031017575820000_dlac008-B3) 2020; 71 Serota (2022031017575820000_dlac008-B5) 2020; 34 Perea (2022031017575820000_dlac008-B8) 2004; 10 Rao (2022031017575820000_dlac008-B9) 2019; 55 Baddour (2022031017575820000_dlac008-B1) 2015; 132 Leahey (2022031017575820000_dlac008-B4) 2019; 6 Iversen (2022031017575820000_dlac008-B2) 2019; 380 Li (2022031017575820000_dlac008-B7) 2000; 30 Kimmel (2022031017575820000_dlac008-B11) 2021; 73 |
References_xml | – volume: 34 start-page: 539 year: 2020 ident: 2022031017575820000_dlac008-B5 article-title: Applying the infectious diseases literature to people who inject drugs publication-title: Infect Dis Clin North Am doi: 10.1016/j.idc.2020.06.010 – volume: 6 start-page: ofz089 year: 2019 ident: 2022031017575820000_dlac008-B4 article-title: High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofz089 – volume: 5 start-page: ofy132 year: 2018 ident: 2022031017575820000_dlac008-B6 article-title: Infectious diseases physicians’ perspectives regarding injection drug use and related infections, United States, 2017 publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofy132 – volume: 30 start-page: 633 year: 2000 ident: 2022031017575820000_dlac008-B7 article-title: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis publication-title: Clin Infect Dis doi: 10.1086/313753 – volume: 132 start-page: 1435 year: 2015 ident: 2022031017575820000_dlac008-B1 article-title: Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association publication-title: Circulation doi: 10.1161/CIR.0000000000000296 – volume: 71 start-page: e650–6 year: 2020 ident: 2022031017575820000_dlac008-B3 article-title: Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa365 – volume: 15 start-page: 20 year: 2021 ident: 2022031017575820000_dlac008-B10 article-title: Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts publication-title: J Addict Med doi: 10.1097/ADM.0000000000000693 – volume: 10 start-page: 96 issue: Suppl 1 year: 2004 ident: 2022031017575820000_dlac008-B8 article-title: Oral versus intravenous therapy in the treatment of systemic mycosis publication-title: Clin Microbiol Infect doi: 10.1111/j.1470-9465.2004.00846.x – volume: 380 start-page: 415 year: 2019 ident: 2022031017575820000_dlac008-B2 article-title: Partial oral versus intravenous antibiotic treatment of endocarditis publication-title: N Engl J Med doi: 10.1056/NEJMoa1808312 – volume: 73 start-page: e2484–92 year: 2021 ident: 2022031017575820000_dlac008-B11 article-title: Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: a nationwide cohort study publication-title: Clin Infect Dis doi: 10.1093/cid/ciaa1126 – volume: 55 start-page: 760 year: 2019 ident: 2022031017575820000_dlac008-B9 article-title: Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis publication-title: Eur J Cardiothorac Surg doi: 10.1093/ejcts/ezy325 |
SSID | ssj0002507472 |
Score | 2.196992 |
Snippet | Abstract
Background
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in... Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite... Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select... |
SourceID | pubmedcentral proquest pubmed crossref oup |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | dlac008 |
SubjectTerms | Antibiotics Drug use Endocarditis Original |
Title | Partial oral antibiotic treatment of endocarditis in patients who inject drugs: a case series |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35156032 https://www.proquest.com/docview/3169987681 https://www.proquest.com/docview/2628686365 https://pubmed.ncbi.nlm.nih.gov/PMC8827559 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEB-0RfBF_Da1HqsIPoW7ZDe7WV9ES0sRrEVauBcJm81uG6lJe7lD_O-dSfbinaC-LIRMSLIzu_OxM78BeJ3NuPGoyGJrfRWT_4Vrztk4TbwwpclFOqNq5E8n8vhcfJxn8xBw60Ja5XpP7DfqqrUUI5_yRKJngMZx8u76JqauUXS6Glpo3IZdgi4jqVZzNcZYUL2jtZyOWI18-s1Y830xra6MnVFHyQ1dtFXftmFm_pktuaF-ju7DvWA3svcDox_ALdc8hDtDJ8mfj-DrKYkAElDBPcPZqsu6RVI2JpKz1jPX4H-SSCzrjtUNC6CqHftx2eI1hWRYtVhddG-ZYRb1GyMBdd1jOD86PDs4jkPnhNgKoZexrriufGKMt6LyQpuSO_QLhHdeKu2lTkqjpVJcS5ugR1NKJ2cEFafyUiTa8iew07SNewbMo_LipcqzTAlRSpGnPrMpPqisJWMvgng9h4UNsOLU3eKqGI63eTHMeRHmPII3I_31AKjxV8pXyJL_Eu2vOVaE1dcVv2UlgpfjbVw3dBhiGteuuiKlmtxccplF8HRg8PgqnlF9OU8jUFusHwkIk3v7TlNf9tjc6LAodNL2_v1Zz-FuSmUUfS7bPuwsFyv3Ao2bZTnpJRjH_CCZwO6Hw5PTL5M-UIDj2ef5L6E5Ajc |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIgQviJtAAYNAPEW7sR07QUIIFaotPcRDK_UFpY5j06CSlM2uqv4pfiMzm4NdJOCpj5Enh-bIfGPPAfAyHgvj0ZGF1voipPgLbc7ZkEdemtwkko-pGnlvX00O5aej-GgNfva1MJRW2f8TFz_qora0Rz4SkcLIAMFx9O7sR0hTo-h0tR-h0arFjrs4x5Ctebv9AeX7ivOtjwebk7CbKhBaKdNZmBYiLXxkjLey8DI1uXCImaV3XunUqzTKTaq0FqmyEaL9XDk1pjZqOslllFqBz70CV6VA06TK9M1o2NNBOIHonA-9IcXom7Hm-3RUnBo7pgmWS75vpZ5uCdb-mZ255O62bsHNDqey961i3YY1V92Ba-3kyou78OUzqRwSUIE_Q-mUeVkjKRsS11ntmauQr6SCs7JhZcW6Jq4NOz-p8Zq2gFgxnX9t3jDDLPpTRgbhmntweCk8vQ_rVV25h8A8OkuR6ySOtZS5kgn3seV4o7aWwGUAYc_DzHZtzGmaxmnWHqeLrOV51vE8gNcD_VnbwOOvlC9QJP8l2ugllnXW3mS_dTOA58My2ikdvpjK1fMm41QDnCih4gAetAIeXiViqmcXPAC9IvqBgHqAr65U5cmiFzgGSBqDwkf__qxncH1ysLeb7W7v7zyGG5xKOBZ5dBuwPpvO3RMEVrP86UKbGRxftvn8Am-POjY |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Partial+oral+antibiotic+treatment+of+endocarditis+in+patients+who+inject+drugs%3A+a+case+series&rft.jtitle=JAC-antimicrobial+resistance&rft.au=Miller%2C+Kaylie&rft.au=Evans%2C+Emily&rft.au=Sheridan%2C+Kathleen+R.&rft.au=Nauriyal%2C+Varidhi&rft.date=2022-03-01&rft.pub=Oxford+University+Press&rft.eissn=2632-1823&rft.volume=4&rft.issue=1&rft_id=info:doi/10.1093%2Fjacamr%2Fdlac008&rft.externalDocID=10.1093%2Fjacamr%2Fdlac008 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2632-1823&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2632-1823&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2632-1823&client=summon |